Sugi Predict

Sugi Predict / Compounds / SCHEMBL713941

SCHEMBL713941

SCHEMBL713941

Cc1cc(CO)ccc1[N+](=O)[O-]

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.54
▸ MAPT P10636 4/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ HSD17B10 Q99714 1/20 0.47
▸ TTR P02766 1/20 0.47
▸ NR3C1 P04150 1/20 0.46
▸ PGR P06401 1/20 0.46
▸ AR P10275 1/20 0.46
▸ RAB9A P51151 4/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ HPGD P15428 1/20 0.45
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31747006 1.00 TSHR (0.54) TSHRMAPTALDH1A1HSD17B10TTR
SCHEMBL5716652 0.86 TSHR (0.53) TSHRMAPTALDH1A1HSD17B10NR3C1
SCHEMBL715634 0.85 ALDH1A1 (0.57) TSHRMAPTALDH1A1HSD17B10TTR
SCHEMBL18138464 0.83 MAPT (0.53) TSHRMAPTALDH1A1HSD17B10NR3C1
SCHEMBL13344094 0.83 MAPT (0.53) TSHRMAPTALDH1A1HSD17B10NR3C1
SCHEMBL515466 0.82 MAPT (0.54) TSHRMAPTALDH1A1TTRSMN1; SMN2
SCHEMBL10662837 0.81 MAPT (0.51) TSHRMAPTALDH1A1HSD17B10NR3C1
SCHEMBL508871 0.81 MAPT (0.51) TSHRMAPTALDH1A1HSD17B10NR3C1
SCHEMBL7988274 0.81 MAPT (0.51) TSHRMAPTALDH1A1HSD17B10NR3C1
SCHEMBL550670 0.81 MAPT (0.51) TSHRMAPTALDH1A1HSD17B10NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486115-B1 ELECTRORHEOLOGIC FLUID COMPRISING ORGANIC SUBSTANCES THAT CAN BE DOPED AND USE THEREOF FRAUNHOFER GES FORSCHUNG (DE) 2015-05-20 — — EP claimed
EP-2486115-A1 ELECTRORHEOLOGICAL FLUID COMPRISING ORGANIC DOPANTS, AND USE THEREOF Fraunhofer Gesellschaft zur Förderung der angewandten Wissenschaft E.V. (DE) 2012-08-15 — — EP claimed
WO-2011042117-A1 ELECTRORHEOLOGICAL FLUID COMPRISING ORGANIC DOPANTS, AND USE THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2011-04-14 — — WO claimed
EP-4668303-A1 CONDUCTIVE POLYMER DISPERSIONS FOR IMPROVED STABILITY PERFORMANCE OF CAPACITORS Heraeus Epurio GmbH (DE) 2025-12-24 — — EP disclosed
EP-4573094-A2 CDK2 INHIBITORS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
US-20240174665-A1 CDK2 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-05-30 — — US disclosed
WO-2024039903-A2 CDK2 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-02-22 — — WO disclosed
CN-110831940-B New substituted azaindoline derivatives as NIK inhibitors 詹森药业有限公司 2023-06-20 — — CN disclosed
US-11555026-B2 AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-01-17 — — US disclosed
US-11458590-B2 Abrasive slurry regeneration method Konica Minolta, Inc. (JP) 2022-10-04 — — US disclosed
EP-3388195-B1 METHOD FOR REGENERATING ABRASIVE SLURRY KONICA MINOLTA INC (JP) 2022-05-04 — — EP disclosed
WO-1996014325-A1 ACYLATED BENZYLGLYCOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION AMERICAN HOME PRODUCTS CORPORATION (US) 1996-05-17 — — WO disclosed
EP-0369627-B1 Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same MITSUI TOATSU CHEMICALS (JP) 1994-12-21 — — EP disclosed
EP-0589665-A2 4,5,6,7-Tetrahydro-1H-imidazo 4,5-c pyridine-6-carboxylic acid amide derivatives as angiotensine II antagonistes KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1994-03-30 — — EP disclosed
EP-0245637-B1 4,5,6,7-Tetrahydro-1H-imidazo[4,5-c]pyridine derivatives and analogs having antihypertensive activity WARNER-LAMBERT COMPANY (US) 1991-10-16 — — EP disclosed
US-5008267-A Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1991-04-16 — — US disclosed
EP-0369627-A2 Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-05-23 — — EP disclosed
US-4816463-A HYPERTENSION WARNER-LAMBERT COMPANY (US) 1989-03-28 — — US disclosed
US-4812462-A 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity WARNER-LAMBERT COMPANY (US) 1989-03-14 — — US disclosed
EP-0245637-A1 4,5,6,7-Tetrahydro-1H-imidazo[4,5-c]pyridine derivatives and analogs having antihypertensive activity WARNER-LAMBERT COMPANY (US) 1987-11-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11555026-B2 AHR inhibitors and uses thereof AHR, ARNT, AIPL1 TSHR 1220/4885MAPT 4714/4885ALDH1A1 299/4885
US-20240174665-A1 CDK2 INHIBITORS AND USES THEREOF CDK2, CDK20, CDK1 TSHR 4345/4885MAPT 2917/4885ALDH1A1 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.